From biotechnology tools to therapy discovery and development: Our platform enhances production yield and the quality of your end product.
Location: United States
Total raised: $8.2M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.01.2026 | - | $5.7M | Inventure ... |
| 22.10.2024 | Seed | $2.5M | - |
Mentions in press and media 15
| Date | Title | Description |
| 03.02.2026 | BII secures €25 million in Novo Nordisk Foundation funding to target early-stage European biosolutions startups | The Novo Nordisk Foundation has allocated up to €25 million for the BioInnovation Institute (BII) to launch a new initiative, ‘Upscalator’, to support Danish and European early-stage startups with facilities, services, and expertise to supp... |
| 25.01.2026 | Octarine Bio Secures €12.8M Series A for Sustainable Pigment Revolution | Octarine Bio, a Danish biotech innovator, secured an additional €5 million, pushing its total Series A funding to €12.8 million. This significant investment fuels the industrial scaling and commercial rollout of its PurePalette platform. Pu... |
| 22.01.2026 | Copenhagen’s Octarine Bio adds €5 million to Series A to advance sustainable colour platform | Octarine Bio, a Danish BioTech company developing a new generation of sustainable pigments through precision fermentation, has successfully secured €5 million to accelerate the industrial-scale validation and commercial rollout of PurePalet... |
| 13.01.2026 | Avenue Biosciences Secures $5.7M for Protein Engineering Revolution | Avenue Biosciences secured $5.7 million in seed extension funding. The Finnish protein engineering firm scales its high-throughput platform. It combines AI and wet-lab biology. This technology optimizes therapeutic protein manufacturing. It... |
| 12.01.2026 | Finnish startup Avenue Biosciences secures €4.8 million to help drugmakers manufacture proteins more reliably | Helsinki-based Avenue Biosciences, a protein engineering technology company, today announced a Seed extension of €4.8 million ($5.7 million) to scale a high-throughput protein engineering tech that accelerates the discovery of protein-based... |
| 12.01.2026 | Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing | Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing Mon, Jan 12, 2026 14:45 CET Report this content Funding will be used to scale the first technology f... |
| 12.01.2026 | Avenue Biosciences Raises $5.7M in Seed Extension Funding | Avenue Biosciences, a Palo Alto, CA-based protein engineering technology company, raised $5.7M in Seed extension funding. The round was led by Balnord, and Tesi, with support from existing investors Voima Ventures, Inventure, University of ... |
| 12.01.2026 | Brado Receives Investment From Santé Ventures | Brado, a St Louis, MO-based healthcare engagement and technology company, received an investment from Santé Ventures. The amount of the deal was not disclosed. As part of the investment, Brado has established Brado AI, a new, dedicated lega... |
| 12.01.2026 | Avenue Biosciences raises $5.7M to scale high-throughput protein engineering | Finnish protein engineering company Avenue Biosciences has raised $5.7 million in a Seed extension funding round co-led by Balnord and Tesi, with support from existing investors Voima Ventures, Inventure, University of Helsinki, and Dimeren... |
| 12.01.2026 | Avenue Biosciences: $5.7 Million Seed Extension Raised To Scale Secretory Pathway Platform For Therapeutic Protein Manufacturing | Avenue Biosciences, a Palo Alto-based protein engineering technology company, has raised $5.7 million in seed extension funding to scale a high-throughput platform designed to measure and modulate the protein secretory pathway, a core cellu... |
Show more